IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4178
Positioning
Market Dominance
Manufacturing
Medical Equipment
$1.8B
Matthew L. Trerotola
Enovis Corporation develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, and other healthcare professionals. The company sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ENOV Enovis CORP | 34 | 41 | 36 | 17 | - | - | -34.3% | -15.7% | 58.8% | -29.8% | -31.7% | 4.5% | 0.0% | 67.0x | $1.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Enovis CORP (ENOV) receives a "Avoid" rating with a composite score of 34.3/100. It ranks #4178 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ENOV.
View All RatingsROIC -33.3% vs WACC 5.0% (spread -38.3%)
GM 59% vs sector 44%, OM -30% vs sector 3%
Capital turnover 0.41x, R&D intensity 5.3%
Rev growth 5%, 10yr history
Interest coverage -63.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Enovis CORP (ENOV) as Avoid with a composite score of 34.3/100 at a current price of $22.89. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Enovis CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.3/100 places it at rank #4178 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 59% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Enovis CORP represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Enovis CORP with an Avoid rating, assigning a composite score of 34.3/100 and 1 out of 5 stars. Ranked #4178 of 7,333 stocks, ENOV falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ENOV's quality score of 41/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -34.3% (sector avg: -1.9%), gross margins of 58.8% (sector avg: 44.1%), net margins of -31.7% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 36/100, ENOV appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 0.64x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Enovis CORP's investment score of 28/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 4.5% vs. a sector average of 6.7% and a return on assets of -15.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Enovis CORP is experiencing notably weak momentum with a score of just 17/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 4.5% year-over-year, while a beta of 1.44 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 56/100, ENOV exhibits average financial resilience. Key stability metrics include a beta of 1.44 and a debt-to-equity ratio of 67.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Enovis CORP's short interest score of 21/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.44), elevated leverage (D/E: 67.00x), small-cap liquidity risk. At $1.8B (small-cap), ENOV carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Enovis CORP is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4178 of 7,333 overall (43rd percentile). Key comparisons include ROE of -34.3% trailing the -1.9% sector median and operating margins of -29.8% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ENOV currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (17) would have the largest impact on the composite score.
ROE 1706% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 34% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1289% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
ELGIN, Ill., February 04, 2026--The Middleby Corporation (NASDAQ: MIDD), a global leader in the foodservice industry, today announced the appointment of Christopher Hix to its Board of Directors, effective February 1. With the addition of Mr. Hix, the Middleby Board expands to eleven members.
John Kleckner, Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on Nov. 25, 2025, signaling potential confidence in the company despite a challenging year with significant quarterly losses.
Enovis has introduced the AltiVate Reverse Glenoid System, a new solution for reverse shoulder arthroplasty. The system offers modular and augmented baseplates, providing surgeons with more options to improve implant longevity and optimize patient outcomes.
Quest Diagnostics is set to report its second-quarter 2024 earnings on July 23. The company's legacy base business and advanced diagnostics offerings are expected to drive growth, while the decline in COVID-19 testing revenues may be a challenge.
Medical technology company Enovis reported Q2 2025 revenue of $564.5 million, up 7% year-over-year, beating analyst estimates. The company raised full-year guidance and saw strong performance in its Reconstructive segment, despite ongoing integration and regulatory challenges.